سعر فامبيرا 10مجم 56 قرص 2026

Fampridine 10 mg prolonged-release tablets (Fampyra), pack of 56.

• Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4–7).Population: AdultsEuropean Medicines Agency (EMA)

• Very common: urinary tract infection (about 12%). Common: insomnia, anxiety, dizziness, headache, balance disorder, paraesthesia, tremor, dyspnoea, pharyngolaryngeal pain, nausea, vomiting, constipation, dyspepsia, back pain, asthenia.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to fampridine or excipients; concurrent treatment with other fampridine (4-aminopyridine) products; prior history or current presentation of seizure; moderate or severe renal impairment (CrCl <50 mL/min); concomitant OCT2 inhibitors (e.g., cimetidine).International label, same formulation · European Medicines Agency (EMA)
• US Ampyra label: contraindicated with any history of seizures, moderate or severe renal impairment (CrCl ≤50 mL/min), or history of hypersensitivity to dalfampridine or 4-aminopyridine.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Increases seizure risk: use with caution with factors lowering seizure threshold and discontinue if a seizure occurs; renal impairment raises plasma levels and adverse reactions (check renal function before and during treatment); caution with OCT2 substrates (carvedilol, propranolol, metformin); serious hypersensitivity/anaphylaxis (mostly in the first week) — discontinue and do not restart; caution with cardiac rhythm or conduction disorders; dizziness/balance disorder may increase falls.International label, same formulation · European Medicines Agency (EMA)

• OCT2 inhibitors (e.g., cimetidine)Contraindicated: OCT2 mediates active renal secretion of fampridine (about 60% of elimination).European Medicines Agency (EMA)
• OCT2 substrates (e.g., carvedilol, propranolol, metformin)Use with caution.European Medicines Agency (EMA)
• Other fampridine (4-aminopyridine) productsConcurrent treatment contraindicated.European Medicines Agency (EMA)

• Limited data in pregnant women; animal studies showed reproductive toxicity; as a precaution it is preferable to avoid fampridine in pregnancy.International label, same formulation · European Medicines Agency (EMA)
• Unknown whether fampridine is excreted in human or animal milk; Fampyra is not recommended during breast-feeding.International label, same formulation · European Medicines Agency (EMA)

• Fampridine: Blocks potassium channels, reducing leakage of ion current through them and prolonging repolarisation, thereby enhancing action potential formation in demyelinated axons.